XKRX
007460
Market cap2mUSD
Oct 08, Last price
2,075.00KRW
1D
-3.94%
1Q
-13.36%
Jan 2017
-73.60%
Name
Aprogen Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Founded in 1971 and headquartered in Seongnam-si, South Korea, Aprogen Medicines Inc. (formerly Aprogen KIC Inc. until its name change in April 2021) specializes in the design, manufacture, and maintenance of plant facilities. Their services cater to crucial sectors including steelwork, petrochemistry, shipbuilding, power generation, and liquefied natural gas (LNG) base industries. The company also provides thermal and cold spray services, a diverse range of clad products such as rolls, plates, wear plates, pipes, and fittings, along with plasma transferred arcs. Furthermore, Aprogen Medicines Inc. offers the Nukon system, a specialized heat-preservation solution vital for ensuring the safe operation of internal piping within pressurized water reactor power plant containment buildings. They are also a supplier of Foamglas, a cellular glass insulation product, and undertake fireproof insulation works for furnaces and boilers, notably at POSCO.
Key people
Vice President · since 2023
Hak Ju Kim
Internal Auditor · since 2018
Director · since 2023
Chief Executive Officer, Director · since 2023
Dong Gyu Ahn
Non-Executive Independent Director · since 2023
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||